Tower Research Capital LLC TRC bought a new position in shares of Bristol-Myers Squibb Co (NYSE:BMY) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 23,094 shares of the biopharmaceutical company’s stock, valued at approximately $1,415,000.
Several other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in shares of Bristol-Myers Squibb by 0.3% during the second quarter. Vanguard Group Inc. now owns 118,661,690 shares of the biopharmaceutical company’s stock worth $6,611,829,000 after acquiring an additional 333,685 shares during the last quarter. BlackRock Inc. raised its position in shares of Bristol-Myers Squibb by 5.0% during the fourth quarter. BlackRock Inc. now owns 104,293,294 shares of the biopharmaceutical company’s stock worth $6,391,093,000 after acquiring an additional 4,945,515 shares during the last quarter. Dodge & Cox raised its position in shares of Bristol-Myers Squibb by 1.6% during the second quarter. Dodge & Cox now owns 29,579,461 shares of the biopharmaceutical company’s stock worth $1,648,168,000 after acquiring an additional 459,271 shares during the last quarter. Jennison Associates LLC raised its position in shares of Bristol-Myers Squibb by 16.2% during the third quarter. Jennison Associates LLC now owns 26,854,242 shares of the biopharmaceutical company’s stock worth $1,711,689,000 after acquiring an additional 3,735,453 shares during the last quarter. Finally, Northern Trust Corp raised its position in shares of Bristol-Myers Squibb by 3.9% during the second quarter. Northern Trust Corp now owns 24,041,862 shares of the biopharmaceutical company’s stock worth $1,339,612,000 after acquiring an additional 910,496 shares during the last quarter. Institutional investors own 71.49% of the company’s stock.
Bristol-Myers Squibb Co (NYSE:BMY) opened at $63.95 on Friday. Bristol-Myers Squibb Co has a 52 week low of $51.56 and a 52 week high of $70.05. The company has a quick ratio of 1.43, a current ratio of 1.55 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $107,913.73, a PE ratio of 108.39, a price-to-earnings-growth ratio of 1.72 and a beta of 0.98.
Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.01. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. The firm had revenue of $5.45 billion during the quarter, compared to analysts’ expectations of $5.35 billion. During the same period in the previous year, the firm earned $0.63 earnings per share. The company’s revenue was up 3.9% on a year-over-year basis. equities research analysts predict that Bristol-Myers Squibb Co will post 3.22 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, May 1st. Shareholders of record on Friday, April 6th will be paid a $0.40 dividend. The ex-dividend date is Thursday, April 5th. This represents a $1.60 dividend on an annualized basis and a yield of 2.50%. Bristol-Myers Squibb’s payout ratio is 271.19%.
A number of research firms have recently weighed in on BMY. Citigroup set a $78.00 target price on Bristol-Myers Squibb and gave the stock a “buy” rating in a research report on Friday, February 16th. Jefferies Group set a $72.00 target price on Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Monday, February 26th. TheStreet cut Bristol-Myers Squibb from a “b” rating to a “c+” rating in a research note on Thursday, March 8th. DZ Bank cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Wednesday, February 28th. Finally, Argus reaffirmed a “buy” rating and set a $66.43 price objective (down from $75.00) on shares of Bristol-Myers Squibb in a research note on Wednesday. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have assigned a buy rating to the stock. Bristol-Myers Squibb presently has an average rating of “Hold” and a consensus target price of $66.79.
ILLEGAL ACTIVITY WARNING: This news story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/03/23/tower-research-capital-llc-trc-invests-1-42-million-in-bristol-myers-squibb-co-bmy.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.